Popular Trials
Anti-infective Agent
Hiprex for Recurring Urinary Tract Infections
This trial aims to see if Hiprex, which releases bacteria-killing formaldehyde in urine, can help women who frequently get urinary tract infections by reducing their recurrence. Hiprex has been compared with another treatment for preventing these infections, showing similar results.
Herbal Medicine
FAHF-2 (TM) for Food Allergy
The increasing prevalence of allergic diseases in westernized countries poses a significant health problem and a tremendous burden on quality of life and healthcare expenditure. Food allergy affects as many as 6% of young children and 3% to 4% of adults. While the majority of children outgrow their allergy to milk, egg, wheat and soy, allergies to peanut, tree nuts, fish and shellfish are often life-long. Currently, there are no treatments that can cure or provide long-term remission from food allergy. Based on our preliminary studies, we hypothesize that our investigational botanical drug, FAHF-2TM, will be a safe and effective herbal therapy for food allergy. We are enrolling those age 12-45 yrs old with allergies to peanut, tree nuts, sesame, fish, and/or shellfish.
1 for Ototoxicity
Aspirin (ASA) has been shown, in an animal model, to attenuate the ototoxic properties of cisplatin. The researchers plan to investigate this in patients undergoing cisplatin chemotherapy. The researchers hypothesise that low-dose aspirin can prevent cisplatin induced ototoxicity in the clinical setting.
Popular Filters
Trials for Urinary Tract Infection Patients
Behavioral Intervention
Discharge Antibiotic Stewardship for Pediatric Infections
This trial tests if a discharge stewardship bundle can reduce inappropriate antibiotic prescribing for kids with 3 common infections. It will involve surveys, interviews and feedback reports.
Virus Therapy
LBP-EC01 for Urinary Tract Infection
This trial is testing LBP-EC01, a virus mixture that targets E. coli bacteria, in patients with recurring UTIs caused by E. coli. The study aims to find the best dose and compare its effectiveness and safety with standard antibiotic treatment.
Trials for Follicular Lymphoma Patients
Monoclonal Antibodies
Rituximab + Lenalidomide + Ibrutinib for Follicular Lymphoma
This trial is testing the side effects and best dose of two drugs, lenalidomide and ibrutinib, when given with a third drug, rituximab, to treat patients with follicular lymphoma that has not been treated before.
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib +/− Rituximab for Chronic Lymphocytic Leukemia
This trial is studying ibrutinib with or without rituximab to see which is more effective in treating patients with chronic lymphocytic leukemia that has come back after treatment.
Phase 3 Trials
Virus Therapy
LBP-EC01 for Urinary Tract Infection
This trial is testing LBP-EC01, a virus mixture that targets E. coli bacteria, in patients with recurring UTIs caused by E. coli. The study aims to find the best dose and compare its effectiveness and safety with standard antibiotic treatment.
Drug-Eluting Stent
TAXUS Express2-SR Stent +1 More for Coronary Artery Disease
The SYNTAX trial is designed to determine the best treatment for patients with complex coronary disease (blocked or narrowed arteries in both the right and left sides of the heart) by randomizing patients to receive either percutaneous coronary intervention (PCI) with polymer-based paclitaxel-eluting TAXUS stents or to coronary artery bypass surgery (CABG).
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Monoclonal Antibodies
Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia
This trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Cancer Vaccine
NeuroVax +1 More for Multiple Sclerosis
This trial is testing NeuroVaxâ„¢, a treatment for people with a worsening form of multiple sclerosis called Secondary Progressive MS. The goal is to see if it can reduce new brain damage over time. The study will compare the effects of NeuroVaxâ„¢ on patients.
Trials With No Placebo
Behavioral Intervention
Discharge Antibiotic Stewardship for Pediatric Infections
This trial tests if a discharge stewardship bundle can reduce inappropriate antibiotic prescribing for kids with 3 common infections. It will involve surveys, interviews and feedback reports.
View More Related Trials
Frequently Asked Questions
Introduction to uti
What are the top hospitals conducting uti research?
When it comes to addressing urinary tract infections (UTI), several hospitals are making remarkable strides in clinical trials. Novo Nordisk Investigational Sites have emerged as leaders in this field, with locations in Lancaster, Miami, and Dallas all actively conducting three UTI trials each. These sites demonstrate a commitment to exploring new avenues for treating this common condition. Interestingly, these hospitals do not currently have any recorded past UTI trials, which indicates that they are at the forefront of pioneering research.
In addition to Novo Nordisk Investigational Sites' efforts, two well-established children's hospitals are also contributing significantly to UTI research. St. Louis Children's Hospital has two ongoing UTI trials and an impressive track record of conducting two previous studies since their first recorded trial in 2020. Meanwhile, the Children's Hospital of Philadelphia is actively engaged in two current UTI trials while holding a rich history of three completed studies since their initial exploration into this area back in 2007.
Urinary tract infections affect millions of individuals worldwide and can cause discomfort and complications if left untreated or recurring frequently. The dedication displayed by these leading institutions showcases the urgency placed on finding effective treatments for such widespread conditions. As researchers tirelessly work towards understanding the intricacies of UTIs and developing innovative solutions, patients can find solace knowing that progress is being made every day thanks to the collaborative efforts between these top hospitals and medical professionals across various locations
Which are the best cities for uti clinical trials?
In the realm of UTI clinical trials, several cities emerge as prominent hubs for research and development. Miami, Florida leads the pack with 15 active trials focusing on LBP-EC01, Sulopenem etzadroxil/probenecid, Semaglutide, and other innovative interventions. Houston, Texas follows closely behind with 13 ongoing studies exploring treatments like LM-302 and As-needed follow-up. New york City boasts 12 active trials investigating promising options such as Semaglutide and Double Voiding. Meanwhile, Boston in Massachusetts showcases 9 active trials delving into Ublituximab, Semaglutide, Cranberry capsules among others. Lastly, Chicago in Illinois also features 9 active trials examining observation techniques alongside potential breakthroughs like Semaglutide and Sulopenem etzadroxil/probenecid. These cities serve as epicenters for UTI clinical research nationwide offering individuals access to cutting-edge studies that may lead to improved treatment options and better outcomes.
Which are the top treatments for uti being explored in clinical trials?
Exciting advancements are taking place in clinical trials for the treatment of urinary tract infections (UTIs). Currently, one standout approach being explored is double voiding. This innovative technique aims to address UTIs through a single active trial, with potential benefits discovered since its listing in 2023. With ongoing research and experimentation, there is hope that this method could offer new solutions for individuals dealing with UTIs and improve their quality of life.
What are the most recent clinical trials for uti?
Recent clinical trials have brought new hope for the treatment of urinary tract infections (UTIs). One such trial focuses on adult patients with ADHD, aiming to understand the correlation between UTIs and this neurodevelopmental disorder. Additionally, a Phase 2 study explored the efficacy of gentamicin-based irrigation in treating UTIs. Another promising trial investigated a combination therapy involving tafasitamab, obinutuzumab, and acalabrutinib for UTI treatment. Furthermore, VNZ/TEZ/D-IVA underwent Phase 3 testing to evaluate its effectiveness against UTIs. Lastly, semaglutide was assessed in a Phase 2 trial as a potential treatment option for UTIs. These pioneering studies pave the way towards improved approaches to combatting these common infections.
What uti clinical trials were recently completed?
Several clinical trials focused on urinary tract infections (UTI) have recently concluded, showcasing the proactive efforts to combat this common condition. In April 2020, GlaxoSmithKline successfully completed a trial investigating Gepotidacin's potential as a treatment option. Similarly, in October 2019, another trial for Gepotidacin by GlaxoSmithKline reached its conclusion. Moreover, Venatorx Pharmaceuticals conducted a study on Cefepime/VNRX-5133 (taniborbactam), which finished in August 2019. Though slightly earlier, Vanderbilt University Medical Center wrapped up their trial examining the efficacy of OnabotulinumtoxinA injection (BTX-A) against UTIs in July 2018. Additionally, Washington University School of Medicine explored fecal microbiota transplant as an alternative approach and completed their trial in February 2018. These collective findings signify commendable dedication to advancing UTI treatments and offer hope for those affected by this prevalent condition.